Agendia and Ferrer inCode Expand MammaPrint(R) Distribution Agreement to Latin America

By Agendia B.v., PRNE
Monday, April 19, 2010

HUNTINGTON BEACH, California and AMSTERDAM, April 20, 2010 - Agendia, a world leader in molecular cancer diagnostics, announced today
it has closed an agreement with Ferrer inCode for the commercialization of
Agendia's FDA-cleared breast cancer recurrence test MammaPrint in Latin

For the successful commercialization of MammaPrint, Ferrer inCode will
leverage the distribution power of its mother company Grupo Ferrer
, the leading Spanish pharmaceutical company in Latin America.
Ferrer products are sold in 18 Latin American countries through subsidiaries,
joint ventures and independent distributors. In key markets such as Brazil,
Argentina, Venezuela, and Peru, Ferrer is ranked either first or second in
terms of distribution power.

"Capitalizing on Ferrer inCode's dominant position on the Iberian
peninsula, we are delighted to expand our strong partnership and make
MammaPrint available to doctors and patients in Latin America as well," said
Bas van der Baan, Vice President Commercial Operation Europe/ROW of Agendia.
"Ferrer has a strong presence in most of the Latin American key markets, most
notably in rapidly emerging countries such as Brazil and Argentina, and has
made great strides towards reimbursement in a number of Latin American

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by
the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro
diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and
analytical validation and reporting systems to ensure patient safety issues
are addressed. Highly accurate, MammaPrint identifies patients with early
metastasis risk - patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown that
chemotherapy particularly reduces early metastasis risk. In planning
treatment, the MammaPrint test results provide doctors with a clear rationale
to assess the benefit of chemotherapy in addition to other clinical
information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIA
compliant service laboratories. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous FDA
clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting-edge genomics platform for tumor gene
expression profiling, the company's tests help physicians more accurately
tailor cancer treatments. Agendia markets four products, with several new
genomic tests under development. In addition, Agendia collaborates with
pharmaceutical companies to develop highly effective personalized drugs in
the area of oncology. Agendia is based in Huntington Beach, California, and
in Amsterdam, The Netherlands.

About Ferrer inCode

Ferrer inCode is the biotech subsidiary of Grupo Ferrer Internacional,
focused on personalized medicine by providing diagnostic orientation,
prognosis and prediction services based on genomics, proteomics, metabolomics
and bioinformatics platforms. The vision of Ferrer inCode is to help doctors
make the most accurate clinical decisions for each patient through advanced
biotechnological services. Ferrer is a privately held European R&D-based
pharmaco-chemical and medical device company headquartered in Barcelona,
. Ferrer is the third largest Spanish pharma company in Spain, with
sales and distribution in over 90 countries.

MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at; Valerie Delva, Account Executive, Ricochet Public Relations, +1-212-679-3300 x131 Office, vdelva at; Olga Fidalgo, Corporate Director, Business Development & Licensing, Grupo Ferrer Internacional, +34-93-600-37-00 Switchboard, +34-93-600-38-67 Office, ofidalgo at

will not be displayed